Maximize Repertoire Diversity. Shorten Your Timelines.
At Twist Biopharma Solutions, your antibody discovery campaigns are driven by experienced scientists on industry-leading in vivo platforms. From our proprietary DiversimAb hyperimmune mouse to camelids for VHH discovery, our team partners with you to design immunization strategies and customize campaigns to ensure the desired molecular profile for even the most difficult targets. Exploit the untapped immune repertories to discover high affinity and functional antibodies by leveraging Twist's comprehensive in vivo discovery portfolio.
Antibody Discovery Powered by the
Best-in-Class Technologies
Alpaca for VHH Discovery
High-Homology and Single-Domain Antibodies for multi-specific antibody development.
Rapid and Predictable Immunization to Antibody Sequence Timelines
DiversimAb 小鼠的超免疫反应可在短短三周内产生适当的滴度，从而实现快速抗体研发。Twist’s B-cell screening on the Beacon platform and the optimized Hybridoma development workflow enables the high-throughput discovery of large, diverse sets of antibodies on a timeline unimaginable a few years ago. Days after tissue collection, the Beacon provides a rich data set about each antibody screened to identify the rare, active, cross-reactive mAbs and VHH antibodies ideal for clinical development.
Find the Ideal Antibody for Your Application
Our suite of high-throughput screening and characterization platforms allows us to identify ideal binders and screen for high-affinity and functionally relevant antibodies early in the discovery process. With our advanced instrumentation suite, we can rapidly characterize leads by ELISA, on-cell screening, antibody kinetics analysis, and epitope binning across all discovery projects.
Experience Freedom from Royalties and Milestones
As of today, your in vivo discovery campaigns have no royalty or milestone burdens We offer flexible project terms, including a fee-for-service option, to accommodate different partners, giving you the most cost-effective, flexible, and de-risked collaboration and path to explore the potential of your lead candidates
听听科学家们怎么说
Twist 是唯一能够按照我们项目所要求的数量和质量标准快速交付 DNA 的合成 DNA 供应商。我们之间的合作不仅限于提供合成基因和抗体，还进一步得到了深化，有助于我们更好地使用 Twist Biopharma 的产品，我们相信这将完善我们的抗体发现工作。”
Robert Carnahan 博士
Vanderbilt 疫苗中心副主任
我们的平台迅速生成并验证治疗具有挑战性的癌症的新靶点。与 Abveris 协作将使我们能够快速识别并选择针对这些靶点的高度特异性抗体，这样我们就可以开发出最好的抗体，以满足特定患者群体的需求。”
首席执行官 JEFF GOLDBERG
Immunitas Therapeutics
了解更多信息
联系我们
我们的抗体专家随时待命，并希望听到更多关于您的发现需求的信息。欢迎挑战性目标！
